Mohamed Gasmi

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Florence Castan, Anthony Lopez et al. · JAMA Oncology · 2022 · 324 citations · Full text

Medicine, Oncology, Surgery +14

Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes

Gwen Lomberk, Yuna Blum, Rémy Nicolle et al. · Nature Communications · 2018 · 277 citations · Full text

Medicine, Cancer Biology, Oncology +17

Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study

Marc Barthet, Marc Giovannini, Nathalie Lesavre et al. · Endoscopy · 2019 · 225 citations

Medicine, Oncology, Surgery +17

Geriatric Factors Predict Chemotherapy Feasibility: Ancillary Results of FFCD 2001-02 Phase III Study in First-Line Chemotherapy for Metastatic Colorectal Cancer in Elderly Patients

Thomas Aparicio, Jean–Louis Jouve, Laurent Teillet et al. · Journal of Clinical Oncology · 2013 · 215 citations · Full text

Medicine, Geriatric Medicine, Oncology +17

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

Anthony Gonçalvès, Marine Gilabert, E. François et al. · Annals of Oncology · 2012 · 214 citations · Full text

Medicine, Oncology, Pharmacology +7